Rare - RARE

Ultragenyx Pharmaceutical Azioni (NASDAQ: RARE)

Ultime notizie per Ultragenyx Pharmaceutical (NASDAQ:RARE) Azioni

Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical Inc

WISDOMTREE ENLSANDERTH UCITS USD ETF

SuperRare - United States Dollar

CANADA RARE EARTH CP ORD by Canada Rare Earth Corp.

Canada Rare Earth Corp

<p>Canaccord Genuity  analyst Whitney Ijem   maintains Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) with a Buy and raises the price target from $109 to $121.</p>


News

Price Target

Analyst Ratings

RARE

Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $121

<p>RBC Capital  analyst Luca Issi   reiterates Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) with a Outperform and maintains $77 price target.</p>


Reiteration

RBC Capital Reiterates Outperform on Ultragenyx Pharmaceutical, Maintains $77 Price Target

<p>Cantor Fitzgerald  analyst Kristen Kluska   reiterates Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) with a Overweight and maintains $116 price target.</p>


Cantor Fitzgerald Reiterates Overweight on Ultragenyx Pharmaceutical, Maintains $116 Price Target

<p>7 analysts have shared their evaluations of Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $101.29, a high estimate of $116.00, and a low estimate of $73.00. Marking an increase of 3.66%, the current average surpasses the previous average price target of $97.71. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730894439_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The standing of Ultragenyx Pharmaceutical among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ed Arce</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$95.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$116.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Yaron Werber</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$73.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$116.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$77.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$116.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$116.00</td>
<td>$116.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ultragenyx Pharmaceutical. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Ultragenyx Pharmaceutical compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Ultragenyx Pharmaceutical's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/RARE/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Ultragenyx Pharmaceutical analyst ratings.</strong></a></p>
<h2>About Ultragenyx Pharmaceutical</h2>
<p>Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.</p>
<h3>Ultragenyx Pharmaceutical: Delving into Financials</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Ultragenyx Pharmaceutical's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of <strong>35.75%</strong>. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Ultragenyx Pharmaceutical's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-89.51%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Ultragenyx Pharmaceutical's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-45.96%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Ultragenyx Pharmaceutical's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-9.0%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.09</strong>.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Evaluating Ultragenyx Pharmaceutical: Insights From 7 Financial Analysts

<p>HC Wainwright &amp; Co.  analyst Ed Arce   maintains Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) with a Buy and raises the price target from $82 to $95.</p>


HC Wainwright & Co. Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $95

Guidance

Ultragenyx Pharmaceutical Sees FY24 Revenue $530M-$550M Vs $536.8M Est

<p>Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) reported quarterly losses of $(1.40) per share which beat the analyst consensus estimate of $(1.53) by 8.5 percent.  The company reported quarterly sales of $139.494 million which beat the analyst consensus estimate of $135.794 million by 2.72 percent.  This is a 42.27 percent increase over sales of $98.052 million the same period last year.</p>


Earnings

Earnings Beats

Ultragenyx Pharmaceutical Q3 2024 GAAP EPS $(1.40) Beats $(1.53) Estimate, Sales $139.494M Beat $135.794M Estimate

<p>Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) is gearing up to announce its quarterly earnings on Tuesday, 2024-11-05. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Ultragenyx Pharmaceutical will report an <strong>earnings per share</strong> (EPS) of $-1.43.</p>
<p>Anticipation surrounds Ultragenyx Pharmaceutical's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Earnings History Snapshot</h3>
<p>In the previous earnings release, the company beat EPS by $0.20, leading to a 14.31% increase in the share price the following trading session.</p>

<p><img src="https://www.benzinga.com/files/images/story/2024/1730736280_0.png" alt="eps graph" /></p>
<h3>Ultragenyx Pharmaceutical Share Price Analysis</h3>
<p>Shares of Ultragenyx Pharmaceutical were trading at $50.99 as of November 01. Over the last 52-week period, shares are up 34.27%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Insights Shared by Analysts on Ultragenyx Pharmaceutical</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Ultragenyx Pharmaceutical.</p>
<p>The consensus rating for Ultragenyx Pharmaceutical is Outperform, based on 6 analyst ratings. With an average one-year price target of $102.33, there's a potential 100.69% upside.</p>
<h3>Understanding Analyst Ratings Among Peers</h3>
<p>The below comparison of the analyst ratings and average 1-year price targets of ADMA Biologics, Alkermes and TG Therapeutics, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.</p>
<ul>
<li>As per analysts' assessments, ADMA Biologics is favoring an Buy trajectory, with an average 1-year price target of $19.0, suggesting a potential 62.74% downside.</li>
<li>Alkermes is maintaining an Outperform status according to analysts, with an average 1-year price target of $38.25, indicating a potential 24.99% downside.</li>
<li>The prevailing sentiment among analysts is an Buy trajectory for TG Therapeutics, with an average 1-year price target of $40.4, implying a potential 20.77% downside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
<p>The peer analysis summary provides a snapshot of key metrics for ADMA Biologics, Alkermes and TG Therapeutics, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ultragenyx Pharmaceutical</td>
<td>Outperform</td>
<td>35.75%</td>
<td>$125.75M</td>
<td>-45.96%</td>
</tr>
<tr>
<td>ADMA Biologics</td>
<td>Buy</td>
<td>78.29%</td>
<td>$57.45M</td>
<td>18.75%</td>
</tr>
<tr>
<td>Alkermes</td>
<td>Outperform</td>
<td>-0.73%</td>
<td>$315.04M</td>
<td>7.17%</td>
</tr>
<tr>
<td>TG Therapeutics</td>
<td>Buy</td>
<td>357.05%</td>
<td>$65.16M</td>
<td>4.07%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Ultragenyx Pharmaceutical ranks at the top for Revenue Growth and Gross Profit, while it ranks at the bottom for Return on Equity among its peers.</p>
<h3>About Ultragenyx Pharmaceutical</h3>
<p>Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.</p>
<h3>Financial Insights: Ultragenyx Pharmaceutical</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Ultragenyx Pharmaceutical displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately <strong>35.75%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-89.51%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Ultragenyx Pharmaceutical's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-45.96%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Ultragenyx Pharmaceutical's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-9.0%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Ultragenyx Pharmaceutical's debt-to-equity ratio is below the industry average at <strong>0.09</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<p><a href="https://www.benzinga.com/quote/RARE/earnings"><strong>To track all earnings releases for Ultragenyx Pharmaceutical visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Look Ahead: Ultragenyx Pharmaceutical's Earnings Forecast

<p>In the preceding three months, 10 analysts have released ratings for Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $89.2, a high estimate of $116.00, and a low estimate of $46.00. Witnessing a positive shift, the current average has risen by 3.0% from the previous average price target of $86.60.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729540850_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Ultragenyx Pharmaceutical by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yaron Werber</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$73.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$116.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$77.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$116.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$116.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$81.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Tiago Fauth</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$76.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$116.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Neutral</td>
<td>$46.00</td>
<td>$43.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Ultragenyx Pharmaceutical. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Ultragenyx Pharmaceutical compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Ultragenyx Pharmaceutical's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/RARE/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Ultragenyx Pharmaceutical analyst ratings.</strong></a></p>
<h2>Discovering Ultragenyx Pharmaceutical: A Closer Look</h2>
<p>Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.</p>
<h3>Unraveling the Financial Story of Ultragenyx Pharmaceutical</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Ultragenyx Pharmaceutical's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>35.75%</strong> as of 30 June, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Ultragenyx Pharmaceutical's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-89.51%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Ultragenyx Pharmaceutical's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-45.96%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-9.0%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.09</strong>.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Decoding 10 Analyst Evaluations For Ultragenyx Pharmaceutical

<p>TD Cowen  analyst Yaron Werber   maintains Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) with a Buy and raises the price target from $61 to $73.</p>


TD Cowen Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $73

Biotech

General

Ultragenyx Receives FDA Breakthrough Therapy Designation For Setrusumab (UX143) To Reduce Fracture Risk In Osteogenesis Imperfecta Types I, III, And IV For Patients Aged 2 And Older

Ultragenyx Provides Update on Stage 1 Cohorts In Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy For Treatment Of Wilson Disease

<p>In the latest quarter, 10 analysts provided ratings for Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Ultragenyx Pharmaceutical, revealing an average target of $89.7, a high estimate of $116.00, and a low estimate of $45.00. Marking an increase of 1.59%, the current average surpasses the previous average price target of $88.30. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726855217_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>A comprehensive examination of how financial experts perceive Ultragenyx Pharmaceutical is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$116.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$116.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$81.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Tiago Fauth</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$76.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$116.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Neutral</td>
<td>$46.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$111.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ultragenyx Pharmaceutical. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ultragenyx Pharmaceutical compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Ultragenyx Pharmaceutical's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Ultragenyx Pharmaceutical's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/RARE/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Ultragenyx Pharmaceutical analyst ratings.</strong></a></p>
<h2>Delving into Ultragenyx Pharmaceutical's Background</h2>
<p>Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.</p>
<h3>Ultragenyx Pharmaceutical's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Ultragenyx Pharmaceutical's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately <strong>35.75%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Ultragenyx Pharmaceutical's net margin is impressive, surpassing industry averages. With a net margin of <strong>-89.51%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Ultragenyx Pharmaceutical's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-45.96%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Ultragenyx Pharmaceutical's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-9.0%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.09</strong>.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Breaking Down Ultragenyx Pharmaceutical: 10 Analysts Share Their Views

<p>The family of Henrietta Lacks has filed a federal lawsuit in Maryland against <strong>Novartis AG</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) and <strong>Viatris Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>), alleging the companies profited unlawfully from the use of her tissue cells, known as &#8220;HeLa&#8221; cells.</p>
<p>The Lacks estate claims these cells, which were taken without her knowledge in the 1950s, have been crucial to the companies&#8217; drug developments without any compensation or permission granted to her estate.</p>
<p>Ben Crump, the Lacks family attorney, emphasized the historical exploitation of Black individuals in medical research, highlighting Lacks&#8217; story as a stark example.</p>
<p>The lawsuit follows previous actions against <strong>Thermo Fisher Scientific Inc </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), which has since been settled, and ongoing litigation against <strong>Ultragenyx Pharmaceutical Inc </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>).</p>
<p><strong>Related: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38968851/ultragenyx-faces-lawsuit-over-alleged-unjust-use-of-henrietta-lacks-cells" rel="noreferrer noopener">Ultragenyx Faces Lawsuit Over Alleged Unjust Use of Henrietta Lacks&#8217; Cells</a>.</strong></p>
<p>Henrietta Lacks&#8217;s cells were taken from her cervix during cancer treatment in 1951 at a Baltimore hospital.</p>
<p>Reuters noted that these HeLa cells were the first to survive and reproduce indefinitely in lab conditions. Lacks passed away from cervical cancer later that year at the age of 31.</p>
<p>The complaint details how Novartis allegedly used HeLa cells in the development of its herpes drug Famvir, cancer treatment Kymriah, and spinal muscular atrophy therapy Zolgensma.</p>
<p>Viatris is accused of using these cells to test its herpes drug, Denavir, and depression treatment, Mylan-Mirtazapine.</p>
<p>The Lacks family seeks profits from the commercialization of HeLa cells and a court order to prevent further use without permission.</p>
<p><strong>Price Action: </strong>At the last check on Tuesday, NVS stock was up 0.36% at $110.25, and VTRS stock was down 0.30% at $11.53.</p>
<p><em>Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.</em></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/general/biotech/24/08/40168977/bristol-myers-squibb-terminates-cancer-drug-development-program-with-agenus" target="_blank" rel="noreferrer noopener">Bristol Myers Squibb Terminates Cancer Drug Development Program With Agenus</a>.</strong></li>
</ul>
<p><em>Photo via Shutterstock</em></p>


Large Cap

Health Care

Legal

Media

VTRS

Novartis And Viatris Sued Over Unlawful Use Of HeLa Cells Used For Cancer Treatment Drugs

<p>Barclays  analyst Gena Wang   maintains Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) with a Overweight and lowers the price target from $83 to $81.</p>


Barclays Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $81

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new B...

3 Best Stocks to Buy Now, 11/6/2024, According to Top Analysts

Ed Arce, an analyst from H.C. Wainwright, maintained the Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report). The associated price tar...

Ultragenyx Pharmaceutical's Promising Growth and Strategic Advances Justify Buy Rating

H.C. Wainwright raised the firm's price target on Ultragenyx (RARE) to $95 from $82 and keeps a Buy rating on the shares post the Q3 report. The fi...

Ultragenyx price target raised to $95 from $82 at H.C. Wainwright

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on AbbVie (ABBV – Research Report), NeoGenomics (NEO ...

Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), NeoGenomics (NEO) and Ultragenyx Pharmaceutical (RARE)

Wells Fargo analyst Tiago Fauth has maintained their bullish stance on RARE stock, giving a Buy rating today. Tiago Fauth's rating is based on seve...

Promising Developments and Strategic Progress Drive Buy Recommendation for Ultragenyx Pharmaceutical

In a report released yesterday, Kristen Kluska from Cantor Fitzgerald maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report)...

Ultragenyx Pharmaceutical (RARE) Receives a Buy from Cantor Fitzgerald

In a report released today, Christopher Raymond from Piper Sandler maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report), w...

Piper Sandler Keeps Their Buy Rating on Ultragenyx Pharmaceutical (RARE)

In a report released today, Dae Gon Ha from Stifel Nicolaus maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report), with a p...

Stifel Nicolaus Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)

In a report released today, Liisa Bayko from Evercore ISI maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report), with a pri...

Evercore ISI Sticks to Its Buy Rating for Ultragenyx Pharmaceutical (RARE)

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report) today. The company's ...

Comments

Ultragenyx Pharmaceutical

Notizie

Ultime notizie per Ultragenyx Pharmaceutical (NASDAQ:RARE) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO